Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06897280 · ClinicalTrials.gov registry record · Phase 4
Clinical Trial of MED HF10™ Spinal Cord Stimulation for the Treatment of Chronic Pain
A Phase 4 study of Chronic, Intractable Back Pain And/or Leg Pain, sponsored by Nevro.
- Active
- Registry status
- Phase 4
- Development phase
- 25
- Enrollment target
- 1
- Study location
NCT06897280: Active Phase 4 study of Chronic, Intractable Back Pain And/or Leg Pain, sponsored by Nevro.
NCT06897280 is a Phase 4 study of Chronic, Intractable Back Pain And/or Leg Pain that is active but no longer recruiting, run by Nevro. The registered enrollment target is 25 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06897280, a Phase 4 study of Chronic, Intractable Back Pain And/or Leg Pain, is active but no longer recruiting, sponsored by Nevro.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 4
- Development phase
- 25 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a single-center, prospective, non-randomized exploratory study in subjects with chronic, intractable back pain and/or leg pain per the center's routine practice. The primary endpoint is the distribution of responders by 'lowest preferred pulse dose (PD)' setting, where a subject is a responder to the lowest PD setting they preferred prior to entering the Observational period. The study is performed in patients who already have Nevro SCS devices implanted.
Primary Outcome
Starting from a standardized low pulse dose (PD) setting, subjects will try progressively lower PD settings depending upon their response to each setting, to arrive at the lowest PD setting they prefer. Up to 5 PD settings will be tried by each subject.
Conditions Studied
Interventions
- DEVICE SCS Device Program Setting
Study Locations (1)
Kansas
- Neuroscience Research Center - Overland Park
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2021-11-16 |
| Est. Completion | 2026-12 |
| Phase | Phase 4 |
What the registry record for NCT06897280 still lists
NCT06897280 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (95% lower).
The record links to 1 condition, with Chronic, Intractable Back Pain And/or Leg Pain appearing as the primary indexed condition, and to 1 intervention - of which SCS Device Program Setting is the first listed.
NCT06897280 reports a single indexed study location in Kansas.
Frequently Asked Questions
What is clinical trial NCT06897280 about?
NCT06897280 is a clinical study titled "Clinical Trial of MED HF10™ Spinal Cord Stimulation for the Treatment of Chronic Pain". This is a single-center, prospective, non-randomized exploratory study in subjects with chronic, intractable back pain and/or leg pain per the center's routine practice. The primary endpoint is the distribution of responders by 'lowest preferred pulse dose (PD)' setting, where a subject is a respond...
What is the current status of trial NCT06897280?
This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 25 participants. The study started on 2021-11-16. Estimated completion is 2026-12.
What conditions does trial NCT06897280 study?
This clinical trial studies the following conditions: Chronic, Intractable Back Pain And/or Leg Pain.
What interventions are being tested in trial NCT06897280?
The interventions under investigation include: SCS Device Program Setting (DEVICE).
Who is sponsoring clinical trial NCT06897280?
This trial is sponsored by Nevro, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06897280 being conducted?
This trial has 1 study location across Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06897280's enrollment target sits among peer trials
25 1669th of 2000 higher than 303 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI